Company profile
UK company 11700555, incorporated on 28 November 2018.
Phenotypeca
Phenotypeca Limited is a UK company with status Active founded in 2018 based in East Midlands.
Company number 11700555
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
PSC08 | Transaction MzUzOTkwMDUxNmFkaXF6a2N4
Published 20 Aug 2026 08:38
PSC07 | Transaction MzUzOTkwMDM3NmFkaXF6a2N4
Published 20 Aug 2026 08:37
TM01 | Transaction MzUzOTkwMDE5OWFkaXF6a2N4
Published 20 Aug 2026 08:35
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
Phenotypeca produces bakers yeast strains for the use in biotechnology processes.
Phenotypeca provides novel biologics production strains of the regulatory friendly baker's yeast, Saccharomyces cerevisiae for the manufacture of biologicals. We offer world leading yeast technology to rapidly provide cost-effective production strains optimised for specific biotechnology processes. This is achieved by harnessing the natural diversity in up to a billion different yeast cells to identify those with the ideal phenotypes and performance characteristics for industrial process conditions. Working with our customers we aim to improve access to life-saving medicines and promote sustainable manufacturing. With baker's yeast now fully established for the safe and economic production of FDA approved biologics, such as insulins and vaccines, our technology is ideal for taking bioprocesses to the next level.
As a recent startup there is limited impact at the moment. There are 6 salaried employees, one full time research scientist, a scientific officer, a research director, business director and tech support. An Innovate UK award for proof of principle was awarded in January 2020 which subcontracts some work to the University lab in Leicester.
1 Oct 2021 to 31 Jan 2023
Recombinant therapeutic proteins and many vaccines are costly to manufacture. Current state-of-the-art protein expression systems include: * Mammalian Chinese Hamster Ovary (CHO) and HEK293 systems. _Limitations:_ Slow-growing cells, expensive media, high energy burden (e.g., for supplying CO2, and for heating the cell cultures), high environmental burden...
1 Jun 2020 to 31 Mar 2021
Phenotypeca Ltd is a biotechnology company based in the University of Nottingham's Synthetic Biology Research Centre developing next-generation yeast for the manufacture of recombinant proteins, such as biopharmaceuticals. Using a genetically diverse collection of natural baker's yeast engineered for large-scale industrial processes we breed up to a billi...
1 Jan 2020 to 30 Sep 2021
Recombinant protein expression is the keystone manufacturing technique supporting production of many biological therapies. A large number of protein expression systems exist, but the majority of biological drugs and protein products that are approved for clinical use have been manufactured using mammalian cell culture techniques. These manufacturing proce...
